| pubmed-article:9240689 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9240689 | lifeskim:mentions | umls-concept:C0021400 | lld:lifeskim |
| pubmed-article:9240689 | lifeskim:mentions | umls-concept:C0013710 | lld:lifeskim |
| pubmed-article:9240689 | lifeskim:mentions | umls-concept:C0008051 | lld:lifeskim |
| pubmed-article:9240689 | lifeskim:mentions | umls-concept:C0598829 | lld:lifeskim |
| pubmed-article:9240689 | lifeskim:mentions | umls-concept:C0887892 | lld:lifeskim |
| pubmed-article:9240689 | pubmed:dateCreated | 1997-8-14 | lld:pubmed |
| pubmed-article:9240689 | pubmed:abstractText | A tissue culture method using MDCK cells grown under serum-free conditions was developed to produce an inactivated influenza subunit vaccine. The first clinical data suggest it to be equal to the conventional egg-derived influenza subunit vaccine. In a double-blind controlled trial, 2 groups (n = 57 each) of adult volunteers were immunized with experimental bivalent influenza subunit vaccine derived from either MDCK cells or hens' eggs. Each vaccine contained 15 microg of hemagglutinin of influenza A/Taiwan/1/186 (H1N1) and 15 microg of hemagglutinin of B/Panama/45/90. No clinically relevant adverse reactions were observed in either vaccine group, and the incidence of systemic and local vaccine reactions was comparable in both groups. Standard hemagglutination inhibition antibody titers were determined using both MDCK- and egg-derived test antigens. The data reveal that both vaccines are safe and well-tolerated and meet the criteria for immunogenicity as stated in the European Community's "Harmonisation of Requirements for Influenza Vaccines." | lld:pubmed |
| pubmed-article:9240689 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9240689 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9240689 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9240689 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9240689 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9240689 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9240689 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:9240689 | pubmed:author | pubmed-author:BrandtSS | lld:pubmed |
| pubmed-article:9240689 | pubmed:author | pubmed-author:PalacheA MAM | lld:pubmed |
| pubmed-article:9240689 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:9240689 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9240689 | pubmed:volume | 176 Suppl 1 | lld:pubmed |
| pubmed-article:9240689 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9240689 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9240689 | pubmed:pagination | S20-3 | lld:pubmed |
| pubmed-article:9240689 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:meshHeading | pubmed-meshheading:9240689-... | lld:pubmed |
| pubmed-article:9240689 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9240689 | pubmed:articleTitle | Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. | lld:pubmed |
| pubmed-article:9240689 | pubmed:affiliation | Solvay Pharmaceuticals, Weesp, The Netherlands. | lld:pubmed |
| pubmed-article:9240689 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9240689 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9240689 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:9240689 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9240689 | lld:pubmed |
